Pfizer Stock News

Pfizer remained flat while the S&P 500 dropped 2.25%, reinforcing its defensive strength in a risk-off market. CY24 revenue reached $63.6B (+6.7% YoY), with non-COVID sales growing 12%, exceeding expectations of 9%-11%. R&D pipeline advanced with 12 approvals, 7 pivotal study starts, and 8 Phase 3 readouts, boosting oncology and obesity treatments.

Pfizer and Arvinas' experimental drug to treat a type of breast cancer met the main goal in a late-stage study, the companies said on Tuesday.

– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival – – Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial – NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfi...

Passive income investors looking to get paid to navigate a more turbulent stock market should look to the many dividend stocks while their yields are still north of 5%.

Investing in dividend stocks can be a great strategy, especially if you pick solid companies that pay reliable and high-yield dividends. While dividend stocks don't always offer the same excitement as high-flying growth stocks or deep value plays, simple is often more.

Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article you will find out who is more promising for long-term investors.

For the better part of the last 2.5 years, the bulls have been calling the shots on Wall Street. The ageless Dow Jones Industrial Average, benchmark S&P 500, and growth-dominated Nasdaq Composite (^IXIC -2.61%) have all soared to numerous record-closing highs.

Need investment income? Dividend stocks are obviously your best bet.